Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours

•During treatment, moderate-to-high baseline functioning and health-related quality-of-life scores were improved/maintained.•Low-to-moderate tumour-related symptom burden remained stable or trended towards clinical improvement, relative to baseline.•Notably there was a rapid and sustained clinically meaningful improvement in cough in patients with non-small-cell lung cancer.•Treatment-related symptoms remained stable or improved; common treatment-related symptoms were absent or low severity.•PRO data reinforce the positive benefit–risk profile of entrectinib and demonstrate a minimal overall treatment burden.